文献速递耳科与耳神经

抗氧化治疗在氨基糖苷类诱导耳毒性中的疗效:一项Meta分析

Antioxidant Therapies in the Treatment of Aminoglycoside-Induced Ototoxicity: A Meta-Analysis.
PubMed 文献 · Laryngoscope · 2024-11-12

该Meta分析检索PubMed、Embase、Web of Science和ClinicalTrials.gov,纳入7项随机对照试验,评估抗氧化治疗对氨基糖苷类耳毒性的效果。汇总分析显示,N-乙酰半胱氨酸(RR 0.112)和阿司匹林(RR 0.229)可降低耳毒性,维生素E未见降低;作者认为缺乏高质量证据。

要点

  • N-乙酰半胱氨酸汇总2项研究显示耳毒性降低(RR 0.112,95%CI 0.032-0.395)。
  • 阿司匹林汇总2项研究显示耳毒性降低(RR 0.229,95%CI 0.080-0.650)。
  • 维生素E单研究未显示较安慰剂降低耳毒性(RR 0.841,95%CI 0.153-4.617)。

核心结论

  • 多项研究显示N-乙酰半胱氨酸和阿司匹林可有效降低氨基糖苷类治疗引起的耳毒性,但缺乏高质量证据。
  • 作者认为需进一步研究阿司匹林和N-乙酰半胱氨酸是否提供长期获益,以及其他有前景的抗氧化剂能否从动物模型转化。

研究设计与样本

  • 系统综述与Meta分析,检索PubMed、Embase、Web of Science和ClinicalTrials.gov,检索时间为2024年8月。
  • 纳入7项在人类中开展的随机对照试验,评估抗氧化药物治疗后氨基糖苷类耳毒性的耳科结局。

主要发现

  • 系统综述共获得2037条结果,其中7项研究符合纳入标准。
  • N-乙酰半胱氨酸在4项研究中 investigated,阿司匹林在2项研究中 investigated,维生素E在1项研究中 investigated。
  • 6项研究评估给药后长达8周的抗氧化治疗获益,1项研究测试受试者1年后的听力。
  • 汇总分析中,2项评估N-乙酰半胱氨酸的研究显示耳毒性降低幅度最大(RR 0.112,95%CI 0.032-0.395;p=0.0007;I²=18%)。
  • 2项评估阿司匹林的研究显示耳毒性降低(RR 0.229,95%CI 0.080-0.650;p=0.0057;I²=0%);1项维生素E研究未发现较安慰剂降低耳毒性(RR 0.841,95%CI 0.153-4.617;p=0.8416)。

关键数值与推荐

  • N-乙酰半胱氨酸汇总2项研究:RR 0.112,95%CI 0.032-0.395;p=0.0007;I²=18%。
  • 阿司匹林汇总2项研究:RR 0.229,95%CI 0.080-0.650;p=0.0057;I²=0%。
  • 维生素E单研究:RR 0.841,95%CI 0.153-4.617;p=0.8416。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者指出缺乏高质量证据。
  • 作者认为需进一步研究阿司匹林和N-乙酰半胱氨酸是否提供长期获益,以及其他有前景的抗氧化剂能否从动物模型转化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: A feared complication of aminoglycoside treatment is ototoxicity, which is theorized to be attributed to the production of aminoglycoside-induced reactive oxygen species. Previous studies using animal models have suggested that numerous therapies targeting reducing oxidative stress may prevent ototoxicity from aminoglycosides. However, few clinical studies have been conducted on these antioxidants. This systematic review and meta-analysis examines the effectiveness of antioxidant therapies in the treatment of aminoglycoside-induced ototoxicity. DATA SOURCES: PubMed, Embase, Web of Science, and ClinicalTrials.gov. REVIEW METHOD: A literature search was conducted in August 2024. This review sought randomized controlled trials to be conducted on humans to examining otologic outcomes in aminoglycoside-induced ototoxicity following administration of medications intended to reduce oxidative stress. RESULTS: A systematic review yielded 2037 results, of which seven studies met inclusion criteria. N-acetylcysteine (NAC) was investigated in four studies, aspirin in two studies, and vitamin E in one study. Six studies examined the benefit of antioxidant treatments for up to 8 weeks after administration while one study tested subjects' hearing after 1 year. In pooled analysis, two studies assessing NAC showed the greatest reduction in ototoxicity (RR 0.112, 95% CI, 0.032-0.395; p = 0.0007; I2 = 18%), followed by two studies examining aspirin (RR 0.229, 95% CI, 0.080-0.650; p = 0.0057; I2 = 0%). One study performed with vitamin E did not find a reduction in ototoxicity compared to the placebo (RR 0.841, 95% CI, 0.153-4.617; p = 0.8416). CONCLUSIONS: Multiple studies have shown that NAC and aspirin are effective in reducing ototoxicity from treatment with aminoglycosides. However, there is a lack of high-quality evidence. Additional studies should examine whether aspirin and N-acetylcysteine provide long-term benefit, and which of the other promising antioxidants translate from animal models. LEVEL OF EVIDENCE: NA Laryngoscope, 135:1278-1286, 2025.

来源:Laryngoscope,查看原文。版权归原作者所有。

引用

  1. Gaffney PJ, Shetty KR, Yuksel S, et al. Antioxidant Therapies in the Treatment of Aminoglycoside-Induced Ototoxicity: A Meta-Analysis. Laryngoscope. 2024. PMID: 39530276. doi:10.1002/lary.31902

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。